A detailed history of Thompson Investment Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Thompson Investment Management, Inc. holds 9,750 shares of NBIX stock, worth $1.22 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
9,750
Previous 7,900 23.42%
Holding current value
$1.22 Million
Previous $1.09 Million 3.22%
% of portfolio
0.17%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$114.58 - $153.15 $211,973 - $283,327
1,850 Added 23.42%
9,750 $1.12 Million
Q2 2024

Jul 08, 2024

BUY
$130.86 - $143.19 $35,986 - $39,377
275 Added 3.61%
7,900 $1.09 Million
Q1 2024

Apr 12, 2024

SELL
$130.4 - $143.74 $9,780 - $10,780
-75 Reduced 0.97%
7,625 $1.05 Million
Q4 2023

Jan 16, 2024

SELL
$106.07 - $132.76 $60,990 - $76,337
-575 Reduced 6.95%
7,700 $1.01 Million
Q3 2023

Oct 30, 2023

SELL
$94.02 - $117.1 $31,026 - $38,643
-330 Reduced 3.83%
8,275 $930,000
Q2 2023

Jul 10, 2023

BUY
$89.53 - $104.87 $33,573 - $39,326
375 Added 4.56%
8,605 $811,000
Q1 2023

Apr 24, 2023

BUY
$94.11 - $123.02 $162,339 - $212,209
1,725 Added 26.52%
8,230 $833,000
Q3 2022

Oct 17, 2022

SELL
$92.03 - $107.81 $119,639 - $140,153
-1,300 Reduced 16.66%
6,505 $691,000
Q1 2022

Apr 20, 2022

BUY
$72.45 - $94.81 $36,225 - $47,405
500 Added 6.84%
7,805 $732,000
Q4 2021

Feb 07, 2022

BUY
$79.65 - $106.22 $29,868 - $39,832
375 Added 5.41%
7,305 $622,000
Q2 2021

Aug 10, 2021

BUY
$89.43 - $102.27 $223,575 - $255,675
2,500 Added 56.43%
6,930 $674,000
Q4 2020

Jan 19, 2021

BUY
$86.91 - $108.33 $60,837 - $75,831
700 Added 18.77%
4,430 $425,000
Q3 2020

Oct 13, 2020

BUY
$96.16 - $135.15 $31,732 - $44,599
330 Added 9.71%
3,730 $359,000
Q2 2020

Jul 23, 2020

BUY
$85.09 - $130.36 $289,306 - $443,224
3,400 New
3,400 $415,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Thompson Investment Management, Inc. Portfolio

Follow Thompson Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Thompson Investment Management, Inc. with notifications on news.